Last reviewed · How we verify

PIB 0.2% ropivacaine — Competitive Intelligence Brief

PIB 0.2% ropivacaine (PIB 0.2% ropivacaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide class). Area: Anesthesia.

marketed Local anesthetic (amide class) Voltage-gated sodium channels Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

PIB 0.2% ropivacaine (PIB 0.2% ropivacaine) — University Health Network, Toronto. Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PIB 0.2% ropivacaine TARGET PIB 0.2% ropivacaine University Health Network, Toronto marketed Local anesthetic (amide class) Voltage-gated sodium channels
Levobupivacaine without epinephrine Levobupivacaine without epinephrine Pontificia Universidad Catolica de Chile marketed Local anesthetic (amide) Voltage-gated sodium channels
bupivacaine 0.25 % injection bupivacaine 0.25 % injection Ain Shams University marketed Local anesthetic (amide class) Voltage-gated sodium channels
Bupivacaine 0.167% Bupivacaine 0.167% Bozyaka Training and Research Hospital marketed Local anesthetic Voltage-gated sodium channels
Intravenous Lidocaine Intravenous Lidocaine Khon Kaen University marketed Local anesthetic; antiarrhythmic agent Voltage-gated sodium channels
Bupivacaine (Hyperbaric 0.5%) Bupivacaine (Hyperbaric 0.5%) Guy's and St Thomas' NHS Foundation Trust marketed Local anesthetic Voltage-gated sodium channels
Paravertebral block using local anesthetic Paravertebral block using local anesthetic University of Wisconsin, Madison marketed Local anesthetic regional nerve block Voltage-gated sodium channels (non-selective)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide class) class)

  1. Ain Shams University · 2 drugs in this class
  2. Başakşehir Çam & Sakura City Hospital · 2 drugs in this class
  3. TriHealth Inc. · 2 drugs in this class
  4. Centre of Postgraduate Medical Education · 2 drugs in this class
  5. Bozyaka Training and Research Hospital · 2 drugs in this class
  6. Complejo Hospitalario Universitario de Granada · 1 drug in this class
  7. Clinique Saint-Jean, Bruxelles · 1 drug in this class
  8. Hospital Clínico Universitario de Valencia · 1 drug in this class
  9. Fundacion Clinica Valle del Lili · 1 drug in this class
  10. Federal University of Minas Gerais · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PIB 0.2% ropivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/pib-0-2-ropivacaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: